Academic-Community Co-Management: Keeping Patients on Therapy and on Track

In this segment, our panel gets into the specifics of how academic and community oncologists can work together to ensure patients on tebentafusp stay on therapy and receive the right guidance throughout their treatment. You will hear how panelists structure the handoff after induction, what direct physician-to-physician communication looks like in practice, and what community oncologists most need to understand about tebentafusp's unique response kinetics before they take over ongoing care. The panel also addresses two common real-world scenarios: the snowbird patient who wants to receive treatment in a different location seasonally, and the patient with mild liver enzyme elevations that can look concerning but are distinct from checkpoint-induced hepatitis and should not prompt premature discontinuation of a therapy that may be providing meaningful benefit.